Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 96 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR 5 ways cancer can impact sexual wellbeing May 17, 2023 Nivolumab vs Sorafenib in First-Line Treatment of Advanced Hepatocellular Carcinoma July 1, 2020 Join the Great American Smokeout for a Healthier Tomorrow November 14, 2023 Updated ROAR Analysis Confirms the Benefit of Dabrafenib Plus Trametinib in... January 31, 2022 Load more HOT NEWS Pembrolizumab Continues to Demonstrate Durable Efficacy with No New Safety Signals... How to Strengthen Your Immune System: Part 2 Nivolumab Appears to Boost Cure Rate in Advanced Hodgkin Lymphoma SBRT Emerging as an Important Treatment for Early-Stage Kidney Cancer
